← All trials
NCT05649059
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2023
- Primary completion
- Sep 30, 2024
- Completion date
- May 31, 2025
- First posted
- Dec 13, 2022
- Last posted
- Dec 13, 2022
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Massachusetts Institute of TechnologyLead sponsor
- Harvard UniversityCollaborator
- Massachusetts Institute of TechnologyOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.